| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Rocket Pharmaceuticals, Inc. (RCKT) has 10 insiders with recent SEC Form 4 filings, including 9 buys and 1 sell. RCKT is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 19.19M | $66.39M | - | |
| CEO | 778.3K | $2.69M | - | |
| COO | 407.2K | $1.41M | - | |
| Other | 383.8K | $1.33M | - | |
| Other | 299.1K | $1.03M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Aug 1, 2018 | Yalamanchi Naveen | Director | Sell | 637 | $22.00 | $14,014.00 | -0.6% | |
| Jan 6, 2017 | Southwell David P69 | President And CEO | Buy | 60,000 | $1.75 | $105,000.00 | +2,170% | |
| May 13, 2016 | Carroll J Martin53 | Director | Buy | 10,000 | $9.03 | $90,294.00 | New | |
| Feb 23, 2015 | Pitango Venture Capital Principals Fund Iv, L.P. | 10% Owner | Buy | 212,375 | $6.00 | $1,274,250.00 | +19.7% | |
| Feb 23, 2015 | Medimmune Ventures, Inc. | 10% Owner | Buy | 416,667 | $6.00 | $2,500,002.00 | +27.8% | |
| Feb 23, 2015 | Karabelas Argeris N73 | Director, 10% Owner | Buy | 603,832 | $6.00 | $3,622,992.00 | +36.1% | |
| Feb 23, 2015 | Rho Ventures IV Qp LP | 10% Owner | Buy | 958,226 | $6.00 | $5,749,356.00 | +50.1% | |
| Feb 23, 2015 | Care Capital II LLC | 10% Owner | Buy | 603,832 | $6.00 | $3,622,992.00 | +36.1% | |
| Feb 23, 2015 | Kantesaria Devang | 10% Owner | Buy | 814,166 | $6.00 | $4,884,996.00 | +33.5% | |
| Feb 23, 2015 | Devon Park Bioventures LP | 10% Owner | Buy | 814,166 | $6.00 | $4,884,996.00 | +33.5% |